Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,220.04
(
-0.48%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
107.50
(
0.02%
)
Bitcoin
76,783.51
(
-0.81%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 69
Posts 4516
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: mcbio post# 152599

Saturday, 11/17/2012 3:00:59 PM

Saturday, November 17, 2012 3:00:59 PM

Post# of 257580
This (Avastin didn't improve OS in 1st line GBM) would open the market for CDX110 in 1st line EGFRvIII+ GBM if the ph3 trial succeeds. CDX110 + Avastin in recurring GBM with PFS as endpoint is a little bit longer shot to me.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today